bruceine d has been researched along with Carcinoma, Hepatocellular in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Z; Ke, X; Li, C; Li, H; Li, X; Liu, S; Qu, Y; Shen, Y; Wu, G; Xie, N; Xu, X; Yang, N; Yuan, X; Zhang, W; Zhou, J; Zu, X | 1 |
1 other study(ies) available for bruceine d and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Jagged-1 Protein; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proteolysis; Quassins; Sorafenib; Time Factors; Transcription, Genetic; Transfection; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2017 |